Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 436-060-3 | CAS number: - FC 84508 PK
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
A NOAEL and NOEL of 1000 mg/kg bw/day was derived based on no treatment-related effects observed at any of the dose levels tested in the 28-d oral study in rats.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From Aug. 19, 2000 to Mar. 08, 2001
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Principles of method if other than guideline:
- Not applicable
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- The rat has proved to be a suitable species for subacute oral toxicity testing with many different substances and is the species of choice according to the international guidelines
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: HARLAN WINKELMANN Gartenstr. 27, D-33178 Borchen, SPF breeding colony
- Age at study initiation: Approximately 6 wk
- Housing: Macrolon cages (type 4) on soft wood granulate in groups of 5 animals
- Diet: ssniff R/M (V1534), ad libitum, except for the period in which the animals were kept in diuresis cages
- Water: Tap water in plastic bottles, ad libitum, except for the period in which the animals were kept In diuresis cages
- Acclimation period: At least 5 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3 °C
- Humidity (%): 50±20 °C
- Photoperiod (hrs dark / hrs light): 12 h dark/12 h light
IN-LIFE DATES: From Sep. 19, 2000 to Oct. 318, 2000 - Route of administration:
- oral: gavage
- Details on route of administration:
- The oral route is considered to be a potential exposure route in man.
- Vehicle:
- other: Tylose H 4000 G4 PHA, (0.5 % in deion. water)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Test substance was suspended in the concentrations of 1.25, 5.0 and 20 % in Tylose H 4000 G4 PHA (0.5% in deionized water). After each measurement of the body weight, the calculation of the application volume was repeated. The final dosing volume was 5 mL/kg bw
VEHICLE
- Justification for use and choice of vehicle (if other than water): The substance is insoluble in water but gives a stabe and homogeneous suspension in Tylose H 4000 G4 PHA (0.5% in deionized water)
- Concentration in vehicle: 1.25, 5.0 and 20 %
- Amount of vehicle (if gavage): 5 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Verification of concentration in formulation by HPLC in first and last week of treatment
- Duration of treatment / exposure:
- 29 d, 28 applications
- Frequency of treatment:
- Once a day for 28 d
- Dose / conc.:
- 62.5 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 250 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5/sex/dose in main groups
5/sex/dose in recovery groups - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Rationale for animal assignment (if not random): Randomization using computer-generated algorithm
- Rationale for selecting satellite groups: To check the reversibility of the effects, if any
- Post-exposure recovery period in satellite groups: Yes
- Rationale for dose-selection: Acute oral toxicity testing of FC 84508 at a dose of 2000 mg/kg in the rat (only this dose was tested) showed that the median lethal dose (LD50) is above 2000 mg/kg body weight in both male and female animals. The dose of 2000 mg/kg was tolerated by all the animals without signs of intoxication.
Based on these results, dose levels of 62.5, 250 and 1000 mg/kg body weight per day were selected. - Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily in all groups
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once before start of the study and once a week during the study
BODY WEIGHT: Yes
- Time schedule for examinations: weekly once
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE : Yes
- Time schedule for examinations: Weekly once
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period
- Anaesthetic used for blood collection: Yes (intraperitoneal injection of 67 + 6.7 mg/kg bw Ketamine HCl + Xylazine)
- Animals fasted: Yes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: At the termination of the study and after the recovery period
- Anaesthetic used for blood collection: Yes, killed by section of the vena cava cranialis in deep narcosis (intraperitoneal injection of 67 + 6.7 mg/kg bw Ketamine HCl + Xylazine) and exsanguinated
URINALYSIS: Yes
- Time schedule for collection of urine: Few days before termination of the study as well as before the end of the recovery period
- Metabolism cages used for collection of urine: Yes
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: Once before start of the study and once a week during the study
- Dose groups that were examined: All groups
- Battery of functions tested: sensory reactivity, grip strength and motor activity
OTHER: Animals were also examined for opacity of the refracting media of the eyes, damage to the oral mucosa and impairment of dental growth - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all animals were necropsied and checked for macroscopically visible abnormalities. The autopsy included macroscopic examination of the skin, orifices, eyes, teeth, oral mucosa and internal organs.
HISTOPATHOLOGY: Yes, Following tissues/organs were preserved in a suitable fixative and processed for histopathological investigations: adrenal gland, bone marrow (sternum), brain, heart, colon, jejunum, kidneys, liver, lungs, lymph nodes (mandibular and iliac), ovaries, uterus, thyroid and parathyroid glands, prostate gland, spleen, stomach, testis, epididymides, thymus, trachea, urinary bladder, N. ischiadicus and spinal cord(cervical), - Other examinations:
- Following organs were weighed and the organ to body weight ratios calculated:
Heart , liver, kidneys, adrenal glands, spleen, testes, epididymides, thymus and brain - Statistics:
- Evaluation was performed by l/S DI&A, Aventis Pharma Deutschland GmbH, with the aid of a program package for the evaluation of toxicological studies.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No significant treatment related clinical signs were observed. No deaths occurred throughout the study.
BODY WEIGHT AND WEIGHT GAIN: Body weight gains were statistically significant increased in female animals from the high dose group from Day 25 to 29 of the study, which was an incidental finding
FOOD CONSUMPTION AND COMPOUND INTAKE: Food consumption remained unaffected by the administration of the test substance throughout the study in all dose groups
WATER CONSUMPTION AND COMPOUND INTAKE: Administration of the test substance did not alter the water consumption of the rats
HAEMATOLOGY: A decrease in the coagulation time in females of the intermediate and high dose group was observed at the end of the 28-d treatment period, which was considered to be an incidental finding
CLINICAL CHEMISTRY: Main group: Higher values of chloride in males of the high dose group and of cholesterol in both sexes of the high dose group and decreases in triglyceride values in males in all dose groups were found.
Recovery group: Increases in sodium, calcium, cholesterol, triglycerides, total protein and albumin values as well as a decrease in glucose in males of the high dose group and decreases in uric acid and triglycerides in females of the high dose group were noted.
All these effects were considered incidental effects.
URINALYSIS: Urine volume was significantly decreased in female animals of the high dose group after the 28-d treatment period, which was considered to be an incidental effect
NEUROBEHAVIOUR: Neurotoxicological measurements including 'open field' observations, assessment, of sensory function, and forelimb and hindlimb grip strength were not influenced by the administration of the test substance in all groups.
ORGAN WEIGHTS: Remained unaffected by the administration of the test substance
GROSS PATHOLOGY: Relevant macroscopical changes could not be seen in male or female animals
HISTOPATHOLOGY: NON-NEOPLASTIC: Sporadic histopathological findings were observed in various organs of different animals, randomly distributed over all investigated groups. Type and incidence of these changes were not relevant for the assessment of the test compound
HISTORICAL CONTROL DATA (if applicable): Changes concerning clinical chemistry were within the historical control data range
OTHER FINDINGS: No opacity of the refracting media of the eyes, changes of the oral mucosa or impairment of dental growth was observed. - Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Critical effects observed:
- no
- Conclusions:
- Under the test conditions, the NOAEL and NOEL of the test substance were determined to be above 1000 mg/kg bw/day in rats
- Executive summary:
A study was conducted to assess the sub acute repeated dose toxicity of the test substance in rats according EU Method B.7. and OECD guideline 407 in compliance with GLP
Groups of male and female rats received test substance by oral gavage at dose levels of 0, 62.5, 250 or 1000 mg/kg bw/day for a period of 28 d. On Day 29, 5 males and five females from each group were killed and necropsied. Five males and five females from the control and high dose group were killed and necropsied after a recovery period of 14 d.
Behavior and state of health were observed daily in all groups, Body weights and food consumption were recorded twice weekly, water consumption once weekly. Once before the first treatment and once a week thereafter detailed clinical observations were performed in all animals outside the home cage in a standard arena ('open field'). Additionally, the animals were examined for opacity of the refracting media of the eyes, damage to the oral mucosa and impairment of dental growth.
Neurotoxicological measurements including assessment of sensory function, motor activity, forelimb and hindlimb grip strength were conducted at the end of the treatment period. Hematological examinations, clinical chemistry and urine analysis were carried out at the end of the treatment period and after the recovery period.
During necropsy the animals were examined for macroscopically visible abnormalities, the main organs were weighed and the organ to body weight ratios calculated. Organs and tissues were processed for histopathological examination and checked for microscopically visible changes.
Body weights, hematological and clinical chemistry data, urine data (volume, specific weight), absolute and relative organ weights and neurotoxicological measurements (motor activity, forelimb and hindlimb grip strength) were analyzed with the aid of a statistical program.
No deaths occurred throughout the study. Behavior, state of health, neurotoxicological, hematological and blood serum parameter analysis remained unaffected by the administration of the test substance in all dose groups.
Body weight gain, organ weights and food and water consumption were comparable in control and dose groups. No test substance related changes were detected by urine analysis or at necropsy or histopathology.
In conclusion, repeated administration of test substance did not cause any substance related changes at the doses administered. Hence, under the test conditions, NOAEL and NOEL of the test substance were determined to be above 1000 mg/kg bw/day in rats.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A study was conducted to assess the sub acute repeated dose toxicity of the test substance in rats according EU Method B.7. and OECD guideline 407 in compliance with GLP
Groups of male and female rats received test substance by oral gavage at dose levels of 0, 62.5, 250 or 1000 mg/kg bw/day for a period of 28 d. On Day 29, 5 males and five females from each group were killed and necropsied. Five males and five females from the control and high dose group were killed and necropsied after a recovery period of 14 d. Behavior and state of health were observed daily in all groups, Body weights and food consumption were recorded twice weekly, water consumption once weekly. Once before the first treatment and once a week thereafter detailed clinical observations were performed in all animals outside the home cage in a standard arena ('open field'). Additionally, the animals were examined for opacity of the refracting media of the eyes, damage to the oral mucosa and impairment of dental growth. Neurotoxicological measurements including assessment of sensory function, motor activity, forelimb and hindlimb grip strength were conducted at the end of the treatment period. Hematological examinations, clinical chemistry and urine analysis were carried out at the end of the treatment period and after the recovery period. During necropsy the animals were examined for macroscopically visible abnormalities, the main organs were weighed and the organ to body weight ratios calculated. Organs and tissues were processed for histopathological examination and checked for microscopically visible changes. Body weights, hematological and clinical chemistry data, urine data (volume, specific weight), absolute and relative organ weights and neurotoxicological measurements (motor activity, forelimb and hindlimb grip strength) were analyzed with the aid of a statistical program.
No deaths occurred throughout the study. Behavior, state of health, neurotoxicological, hematological and blood serum parameter analysis remained unaffected by the administration of the test substance in all dose groups. Body weight gain, organ weights and food and water consumption were comparable in control and dose groups. No test substance related changes were detected by urine analysis or at necropsy or histopathology. In conclusion, repeated administration of test substance did not cause any substance related changes at the doses administered. The NOAEL and NOEL of the test substance were determined to be > 1000 mg/kg bw/day in rats (Dr. Seeberger A and Dr. Kauffmann HM, 2001).
A NOAEL and NOEL of above 1000 mg/kg bw/day was derived based on no treatment-related effects observed at any of the dose levels tested in the 28-d oral study in rats.
Justification for classification or non-classification
A NOAEL and NOEL of above 1000 mg/kg bw/day was derived based on no treatment-related effects observed at any of the dose levels tested in the 28-d oral study in rats and therefore based on the results the test substance does not meet the requirement for classification according to according to EC criteria (67/548/EEC) and according to CLP criteria (EC 1272/2008).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.